# A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

> **NCT00402077** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 258 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** pramlintide acetate
- **DRUG:** sibutramine
- **DRUG:** phentermine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00402077
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2015-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402077, "A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00402077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*